



MASSACHUSETTS

Blue Cross Blue Shield of Massachusetts is an Independent Licensee of the Blue Cross and Blue Shield Association

Medical Policy

Small Bowel/Liver and Multivisceral Transplant

Table of Contents

- [Policy: Commercial](#)
- [Policy: Medicare](#)
- [Authorization Information](#)
- [Coding Information](#)
- [Description](#)
- [Policy History](#)
- [Information Pertaining to All Policies](#)
- [References](#)

Policy Number: 632

BCBSA Reference Number: 7.03.05 (For Plan internal use only)

NCD/LCD: National Coverage Determination (NCD) for Intestinal and Multi-Visceral Transplant (260.5)

Related Policies

Isolated Small Bowel Transplant, #[631](#)

Policy

Commercial Members: Managed Care (HMO and POS), PPO, and Indemnity

A small bowel/liver transplant or multivisceral transplant may be **MEDICALLY NECESSARY** for pediatric and adult patients with intestinal failure (characterized by loss of absorption and the inability to maintain protein-energy, fluid, electrolyte, or micronutrient balance) who have been managed with long-term total parenteral nutrition (TPN) and who have developed evidence of impending end-stage liver failure.

A small bowel/liver retransplant or multivisceral retransplant may be **MEDICALLY NECESSARY** after a failed primary small bowel/liver transplant or multivisceral transplant.

In addition to the above information, we do not cover small bowel/liver transplant or multivisceral transplantation when any of the following conditions are present:

- Known current malignancy, including metastatic cancer
- Recent malignancy with high risk of recurrence
 - Note: the assessment of risk of recurrence for a previously treated malignancy is made by the transplant team; providers must submit a statement with an explanation of why the patient with a recently treated malignancy is an appropriate candidate for a transplant.
- History of cancer with a moderate risk of recurrence
- Systemic disease that could be exacerbated by immunosuppression
- Untreated systemic infection making immunosuppression unsafe, including chronic infection
 - Other irreversible end-stage disease not attributed to intestinal failure
- Psychosocial conditions or chemical dependency affecting ability to adhere to therapy

Candidates should meet the following criteria:

- Adequate cardiopulmonary status

- Documentation of patient compliance with medical management.

HIV [human immunodeficiency virus]-positive patients who meet the following criteria, as stated in the 2001 guidelines of the American Society of Transplantation, could be considered candidates for small bowel/liver or multivisceral transplantation:

- CD4 count greater than 200 cells per cubic millimeter for greater than 6 months
- HIV-1 RNA undetectable
- On stable anti-retroviral therapy >3 months
- No other complications from AIDS [acquired immune deficiency syndrome] (e.g., opportunistic infection, including aspergillus, tuberculosis, coccidiosis mycosis, resistant fungal infections, Kaposi's sarcoma, or other neoplasm), and meeting all other criteria for transplantation.

A small/bowel/liver transplant or multivisceral transplant is **INVESTIGATIONAL** in all other situations.

Prior Authorization Information

Inpatient

- For services described in this policy, precertification/preauthorization **IS REQUIRED** for all products if the procedure is performed **inpatient**.

Outpatient

- For services described in this policy, see below for products where prior authorization **might be required** if the procedure is performed **outpatient**.

	Outpatient
Commercial Managed Care (HMO and POS)	This procedure is performed in the inpatient setting.
Commercial PPO and Indemnity	This procedure is performed in the inpatient setting.

CPT Codes / HCPCS Codes / ICD Codes

Inclusion or exclusion of a code does not constitute or imply member coverage or provider reimbursement. Please refer to the member's contract benefits in effect at the time of service to determine coverage or non-coverage as it applies to an individual member.

Providers should report all services using the most up-to-date industry-standard procedure, revenue, and diagnosis codes, including modifiers where applicable.

The following codes are included below for informational purposes only; this is not an all-inclusive list.

The above **medical necessity criteria MUST be met for the following codes to be covered for Commercial Members: Managed Care (HMO and POS), PPO, and Indemnity:**

CPT Codes

CPT codes:	Code Description
44135	Intestinal allotransplantation; from cadaver donor
44136	Intestinal allotransplantation; from living donor
47135	Liver allotransplantation; orthotopic, partial or whole, from cadaver or living donor, any age

HCPCS Codes

HCPCS codes:	Code Description
S2053	Transplantation of small intestine and liver allografts
S2054	Transplantation of multivisceral organs

ICD-10 Procedure Codes

ICD-10-PCS procedure codes:	Code Description
0DY60Z0	Transplantation of Stomach, Allogeneic, Open Approach
0DY60Z1	Transplantation of Stomach, Syngeneic, Open Approach
0FYG0Z0	Transplantation of Pancreas, Allogeneic, Open Approach
0FYG0Z1	Transplantation of Pancreas, Syngeneic, Open Approach
0DY80Z0	Transplantation of Small Intestine, Allogeneic, Open Approach
0DY80Z1	Transplantation of Small Intestine, Syngeneic, Open Approach
0FY00Z1	Transplantation of Liver, Syngeneic, Open Approach
0FY00Z0	Transplantation of Liver, Allogeneic, Open Approach
0DT80ZZ	Resection of Small Intestine, Open Approach
0DT84ZZ	Resection of Small Intestine, Percutaneous Endoscopic Approach
0DYE0Z0	Transplantation of Large Intestine, Allogeneic, Open Approach
0DYE0Z1	Transplantation of Large Intestine, Syngeneic, Open Approach

Description

Solid organ transplantation offers a treatment option for patients with different types of end-stage organ failure that can be lifesaving or provide significant improvements to a patient's quality of life.¹ Many advances have been made in the last several decades to reduce perioperative complications. Available data supports improvement in long-term survival as well as improved quality of life particularly for liver, kidney, pancreas, heart, and lung transplants. Allograft rejection remains a key early and late complication risk for any organ transplantation. Transplant recipients require life-long immunosuppression to prevent rejection. Patients are prioritized for transplant by mortality risk and severity of illness criteria developed by Organ Procurement and Transplantation Network and United Network of Organ Sharing.

Small Bowel/Liver and Multivisceral Transplant

In 2019, 39,719 transplants were performed in the United States procured from almost 11,900 deceased donors and 7,400 living donors. Intestinal transplants occur less frequently than other organ transplants, with 10 or fewer patients receiving liver-intestine transplant each year from 2008 to 2019. <https://optn.transplant.hrsa.gov/data/view-data-reports/national-data/#> Small bowel and liver or multivisceral transplant is usually considered in adults and children who develop serious complications related to parenteral nutrition, including inaccessibility (eg, due to thrombosis) of access sites, catheter-related sepsis, and cholestatic liver disease.

Short Bowel Syndrome

Short bowel syndrome is defined as an inadequate absorbing surface of the small intestine due to extensive disease or surgical removal of a large portion of the small intestine.² In some instances, short bowel syndrome is associated with liver failure, often due to the long-term complications of total parenteral nutrition.

Treatment

A small bowel/liver transplant or a multivisceral transplant includes the small bowel and liver with 1 or more of the following organs: stomach, duodenum, jejunum, ileum, pancreas, and/or colon. The type of transplantation depends on the underlying etiology of intestinal failure, quality of native organs, presence or severity of liver disease, and history of prior abdominal surgeries.³ A multivisceral transplant is indicated when anatomic or other medical problems preclude a small bowel/liver transplant. Complications following small bowel/liver and multivisceral transplants include acute or chronic rejection, donor-specific antibodies, infection, lymphoproliferative disorder, graft-versus-host disease, and renal dysfunction.⁴

Summary

This evidence review addresses transplantation and retransplantation of an intestinal allograft in combination with a liver allograft, either alone or in combination with one or more of the following organs: stomach, duodenum, jejunum, ileum, pancreas, or colon.

For individuals who have intestinal failure and evidence of impending end-stage liver failure who receive a small bowel and liver transplant alone or multivisceral transplant, the evidence includes a registry study and a limited number of case series. Relevant outcomes are OS, morbid events, and treatment-related mortality and morbidity. These transplant procedures are infrequently performed, and few reported case series exist. However, results from the available literature have revealed fairly high postprocedural survival rates. Given these results and the exceedingly poor survival rates of patients who exhaust all other treatments, transplantation may prove not only to be the last option but also a beneficial one. Transplantation is contraindicated for patients in whom the procedure is expected to be futile due to comorbid disease, or in whom posttransplantation care is expected to significantly worsen comorbid conditions. The evidence is sufficient to determine that the technology results in a meaningful improvement in the net health outcome.

For individuals who have a failed small bowel and liver or multivisceral transplant without contraindications for retransplant who receive a small bowel and liver retransplant alone or multivisceral retransplant, the evidence includes case series. Relevant outcomes are overall survival, morbid events, and treatment-related mortality and morbidity. Although limited in quantity, the available post retransplantation data have suggested reasonably high survival rates. Given exceedingly poor survival rates without retransplantation of patients who have exhausted other treatments, evidence of postoperative survival from uncontrolled studies is sufficient to demonstrate that retransplantation provides a survival benefit in appropriately selected patients. Retransplantation is contraindicated for patients in whom the procedure is expected to be futile due to comorbid disease or in whom posttransplantation care is expected to significantly worsen comorbid conditions. The evidence is sufficient to determine that the technology results in a meaningful improvement in the net health outcome.

Policy History

Date	Action
9/2021	Annual policy review. Policy statements unchanged.
1/2021	Medicare information removed. See MP #132 Medicare Advantage Management for local coverage determination and national coverage determination reference.
10/2020	Annual policy review. Description, summary, and references updated. Policy statements unchanged.
10/2019	Annual policy review. Description, summary, and references updated. Policy statements unchanged.
10/2018	Annual policy review. Description, summary, and references updated. Policy statements unchanged.
9/2017	Annual policy review. New references added.
1/2017	Annual policy review. New references added.
1/2016	Clarified coding information.
8/2015	Coding information clarified.
10/2014	Medical policy remediation: New indications for non-coverage. Coding information clarified. Effective 10/1/2014.
4/2014	Coding information clarified.
12/2013	Annual policy review. New medically necessary indications described. Effective 12/1/2013. Coding information clarified.
11/2011-4/2012	Medical policy ICD 10 remediation: Formatting, editing and coding updates. No changes to policy statements.
5/2012	Annual policy review. Changes to policy statements.
11/2010	Reviewed - Medical Policy Group - Gastroenterology, Nutrition and Organ Transplantation. No changes to policy statements.

10/2010	Annual policy review. No changes to policy statements.
6/2010	Annual policy review. Changes to policy statements.
11/2009	Annual policy review. Changes to policy statements.
11/2009	Reviewed - Medical Policy Group - Gastroenterology, Nutrition and Organ Transplantation. No changes to policy statements.
5/2009	Annual policy review. No changes to policy statements.
11/2008	Reviewed - Medical Policy Group - Gastroenterology, Nutrition and Organ Transplantation. No changes to policy statements.

Information Pertaining to All Blue Cross Blue Shield Medical Policies

Click on any of the following terms to access the relevant information:

[Medical Policy Terms of Use](#)

[Managed Care Guidelines](#)

[Indemnity/PPO Guidelines](#)

[Clinical Exception Process](#)

[Medical Technology Assessment Guidelines](#)

References

1. Black CK, Termanini KM, Aguirre O, et al. Solid organ transplantation in the 21 st century. *Ann Transl Med.* Oct 2018; 6(20): 409. PMID 30498736
2. Sulkowski JP, Minneci PC. Management of short bowel syndrome. *Pathophysiology.* Feb 2014; 21(1): 111-8. PMID 24341969
3. Bharadwaj S, Tandon P, Gohel TD, et al. Current status of intestinal and multivisceral transplantation. *Gastroenterol Rep (Oxf).* Feb 2017; 5(1): 20-28. PMID 28130374
4. Loo L, Vrakas G, Reddy S, et al. Intestinal transplantation: a review. *Curr Opin Gastroenterol.* May 2017; 33(3): 203-211. PMID 28282321
5. Blue Cross and Blue Shield Association Technology Evaluation Center (TEC). Small bowel transplants in adults and multivisceral transplants in adults and children. *TEC Assessments.* 1999;Volume 14:Tab 9.
6. Mangus RS, Tector AJ, Kubal CA, et al. Multivisceral transplantation: expanding indications and improving outcomes. *J Gastrointest Surg.* Jan 2013; 17(1): 179-86; discussion p.186-7. PMID 23070622
7. Abu-Elmagd KM, Costa G, Bond GJ, et al. Five hundred intestinal and multivisceral transplantations at a single center: major advances with new challenges. *Ann Surg.* Oct 2009; 250(4): 567-81. PMID 19730240
8. Desai CS, Khan KM, Gruessner AC, et al. Intestinal retransplantation: analysis of Organ Procurement and Transplantation Network database. *Transplantation.* Jan 15 2012; 93(1): 120-5. PMID 22113492
9. Raghu VK, Beaumont JL, Everly MJ, et al. Pediatric intestinal transplantation: Analysis of the intestinal transplant registry. *Pediatr Transplant.* Dec 2019; 23(8): e13580. PMID 31531934
10. Lacaille F, Irtan S, Dupic L, et al. Twenty-eight years of intestinal transplantation in Paris: experience of the oldest European center. *Transpl Int.* Feb 2017; 30(2): 178-186. PMID 27889929
11. Garcia Aroz S, Tzvetanov I, Hetterman EA, et al. Long-term outcomes of living-related small intestinal transplantation in children: A single-center experience. *Pediatr Transplant.* Jun 2017; 21(4). PMID 28295952
12. Dore M, Junco PT, Andres AM, et al. Surgical Rehabilitation Techniques in Children with Poor Prognosis Short Bowel Syndrome. *Eur J Pediatr Surg.* Feb 2016; 26(1): 112-6. PMID 26535775
13. Rutter CS, Amin I, Russell NK, et al. Adult Intestinal and Multivisceral Transplantation: Experience From a Single Center in the United Kingdom. *Transplant Proc.* Mar 2016; 48(2): 468-72. PMID 27109980
14. Lauro A, Zanfi C, Dazzi A, et al. Disease-related intestinal transplant in adults: results from a single center. *Transplant Proc.* Jan-Feb 2014; 46(1): 245-8. PMID 24507060
15. Varkey J, Simren M, Bosaeus I, et al. Survival of patients evaluated for intestinal and multivisceral transplantation - the Scandinavian experience. *Scand J Gastroenterol.* Jun 2013; 48(6): 702-11. PMID 23544434

16. Spence AB, Natarajan M, Fogleman S, et al. Intra-abdominal infections among adult intestinal and multivisceral transplant recipients in the 2-year post-operative period. *Transpl Infect Dis*. Feb 2020; 22(1): e13219. PMID 31778012
17. Nagai S, Mangus RS, Anderson E, et al. Cytomegalovirus Infection After Intestinal/Multivisceral Transplantation: A Single-Center Experience With 210 Cases. *Transplantation*. Feb 2016; 100(2): 451-60. PMID 26247555
18. Timpone JG, Yimen M, Cox S, et al. Resistant cytomegalovirus in intestinal and multivisceral transplant recipients. *Transpl Infect Dis*. Apr 2016; 18(2): 202-9. PMID 26853894
19. Wu GS, Cruz RJ, Cai JC. Acute antibody-mediated rejection after intestinal transplantation. *World J Transplant*. Dec 24 2016; 6(4): 719-728. PMID 28058223
20. Cromvik J, Varkey J, Herlenius G, et al. Graft-versus-host Disease After Intestinal or Multivisceral Transplantation: A Scandinavian Single-center Experience. *Transplant Proc*. Jan-Feb 2016; 48(1): 185-90. PMID 26915866
21. Florescu DF, Qiu F, Langnas AN, et al. Bloodstream infections during the first year after pediatric small bowel transplantation. *Pediatr Infect Dis J*. Jul 2012; 31(7): 700-4. PMID 22466325
22. Wu G, Selvaggi G, Nishida S, et al. Graft-versus-host disease after intestinal and multivisceral transplantation. *Transplantation*. Jan 27 2011; 91(2): 219-24. PMID 21076376
23. Organ Procurement and Transplantation Network (OPTN). Organ Procurement and Transplantation Network Policies. 2018; https://optn.transplant.hrsa.gov/media/1200/optn_policies.pdf. Accessed July 1, 2020.
24. Working Party of the British Transplantation Society. Kidney and Pancreas Transplantation in Patients with HIV. Second Edition (Revised). British Transplantation Society Guidelines. Macclesfield, UK: British Transplantation Society; 2017.
25. Ekser B, Kubal CA, Fridell JA, et al. Comparable outcomes in intestinal retransplantation: Single-center cohort study. *Clin Transplant*. Jul 2018; 32(7): e13290. PMID 29782661
26. Mazariegos GV, Soltys K, Bond G, et al. Pediatric intestinal retransplantation: techniques, management, and outcomes. *Transplantation*. Dec 27 2008; 86(12): 1777-82. PMID 19104421
27. American Gastroenterological Association. American Gastroenterological Association medical position statement: short bowel syndrome and intestinal transplantation. *Gastroenterology*. Apr 2003; 124(4): 1105-10. PMID 12671903
28. Kaufman SS, Atkinson JB, Bianchi A, et al. Indications for pediatric intestinal transplantation: a position paper of the American Society of Transplantation. *Pediatr Transplant*. Apr 2001; 5(2): 80-7. PMID 11328544
29. Center for Medicare & Medicaid Services. National Coverage Determination (NCD) for Intestinal and Multi- Visceral Transplantation (260.5). 2006; <https://www.cms.gov/medicare-coverage-database/details/ncd-details.aspx?NCDId=280&ncdver=2&CoverageSelection=National&Keyword=intestinal&KeywordLookup=Title&KeywordSearchType=And&generalError=Thank+you+for+your+interest+in+the+Medicare+Coverage+Database.+You+may+only+view+the+page+you+attempted+to+access+via+normal+usage+of+the+Medicare+Coverage+ Database.&bc=gAAAAACAAAAAAA%3d%3d&>. Accessed July 1, 2020.